Blog | HemaCare

Stacy Matthews Branch, DVM, PhD


Recent Posts

New Study Shows Cancer Cells Reverting to Stem Cells

Nov 2, 2021 10:30:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Stem Cells

0 Comments

Scientists in Japan created a new tool to study how cancer cells will hide in the body, making it easier to create new cancer cells after treatment.

According to the Centers for Disease Control, cancer is one of the top 5 causes of death in developed countries. Although many advances have been achieved regarding treatment options for different types of cancer, preventing recurrence and bolstering long-term survival in patients with advanced forms of cancer remains a challenge. The persistence of cancer stem cells in the body, which are resistant to conventional treatments, appears to be an important factor leading to cancer recurrence.

Read More

Brain Cancer Vaccine Passes Phase I Human Trial

Sep 21, 2021 11:00:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, T Cells

0 Comments

The vaccine was designed to assist a patient’s immune system target brain tumors more effectively and efficiently.

Gliomas are brain cancers that are considered rare disorders that affect 6.6 out of 100,000 individuals yearly worldwide.

Read More

Cancer CAR T Cell Therapy Adapted to Help Fight Threatening Fungal Infections

Sep 14, 2021 10:00:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, CAR-T, T Cells, Immunotherapy (Immunology)

0 Comments

Cryptococcus fungi infections can be fatal as the immune system struggles to fight off the invaders, but through immunotherapy called CAR T cell therapy, researchers are seeing positive results.

Cryptococcosis, a systemic fungal infection, is caused by the polysaccharide encapsulated yeasts Cryptococcus gatti and Cryptococcus neoformans. The disease can cause pneumonia and meningitis, as well as pathology in other tissues.

Read More

CAR T Cell Therapy Attacks Migrant Cells in the Immune System

Sep 7, 2021 10:10:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, T Cells

0 Comments

The FDA has currently approved CAR-T cell therapies that express CARs recognizing CD19. CD19 is expressed on top of the majority of B cells’ surface, allowing for specific B-cell malignancy therapies.

According to the American Cancer Society, there are approximately 5,690 new cases of and 1,580 deaths from acute lymphocytic anemia (ALL), most of which affect children. More than 18,000 people are diagnosed with diffuse large B-cell lymphoma (DLBCL) yearly, with the majority being people over the age of 60. B cells secrete antibodies that are antigen-specific. T cells work differently by directly attacking pathogenic or infected cells, and they also secrete inflammatory cytokines to induce additional immune cell involvement.

Read More

Genetically Engineered T-Cells May Lead to a New Immunotherapy for Type 1 Diabetes

Aug 31, 2021 10:15:00 AM / by Stacy Matthews Branch, DVM, PhD posted in CAR-T, T Cells

0 Comments

University of Arizona researchers created a new five-module chimeric antigen receptor T cell that has shown potential to fight against Type 1 diabetes.

Type 1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic β cells by pathogenic, autoreactive T cells. Effective and safe immunotherapy approaches to treat T1D would enhance personalized medical approaches to mitigate the effects of pathogenic T-cell–mediated diseases such as T1D. A promising approach is the application of chimeric antigen receptor (CAR) T cells, given its known mechanism and current use to treat other diseases such as hematological cancers.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts